At a glance
- Originator Takeda
- Class Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inborn genetic disorders
Most Recent Events
- 30 Jul 2021 Takeda terminates a phase I trial in Healthy volunteers in USA due to administrative reasons (PO) (NCT04202497)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Inborn genetic disorders(In volunteers) in USA (PO, Capsule)
- 19 Mar 2020 Takeda completes a phase I trial in Healthy volunteers in USA (PO) (NCT04202497)